Regeneron posted its Eylea updates as the company reported ... cholesterol med Praluent, suffered a 19% sales decline to $57 million in the U.S. The company also shares sales on the immunology ...

Regeneron’s shares have jumped 22.3% in the past year against the industry’s decline of 13.6%. Lead drug Eylea’s sales in the United States were $1.34 billion, down 11% year over year ...

Regeneron Pharmaceuticals, Inc. REGN provided business and pipeline updates at the 43rd Annual J.P. Morgan Healthcare Conference. Shares of the company moved up in pre-market trading on Jan. 14.

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

Regeneron’s shares have lost 14.1% year to date compared with the industry’s decline of 4.7%. Image Source: Zacks Investment Research Eylea’s sales in the United States plunged 39% year over ...

Regeneron 'knocks it out of the park' with data for high-dose Eylea: analysts Josh ... it also was a decline from the $3.41 billion sales figure the company posted in the fourth quarter of last ...

Regeneron Pharmaceuticals' (NASDAQ:REGN) stock is trading in the red premarket on Thursday after net product sales of Eylea in the ... therapy REGEN-COV saw a decline of -3.52% Y/Y to $613.2M ...

Regeneron Pharmaceuticals, Inc. REGN delivered better-than-expected fourth-quarter 2022 results even though Eylea sales declined ... against the industry’s decline of 8.1%.

Regeneron Pharmaceuticals, Inc. REGN delivered better-than-expected first-quarter 2023 results even though lead drug Eylea sales declined ... the industry’s decline of 6.2%.

Regeneron’s shares have gained 9.7% in the year so far against the industry’s decline of 23.5% ... Lead drug Eylea’s sales in the United States were $1.45 billion, down 11% year over ...